Skip to main content
An official website of the United States government
Grant Details

Grant Number: 5UC2CA148471-02 Interpret this number
Primary Investigator: Goddard, Katrina
Organization: Kaiser Foundation Research Institute
Project Title: Comparative Effectiveness in Genomic & Personalized Medicine for Colon Cancer
Fiscal Year: 2010


DESCRIPTION (Provided by the applicant): In recent years, genomic or other molecular tests have been recommended for clinical practice in the area of cancer treatment. They are used to identify individuals at high risk, screen and perform early detection, identify prognostic markers, and guide course of therapy. We propose a focused program of research that will investigate the comparative effectiveness of several tests related to colorectal cancer. The proposed study is a collaboration of several of the member sites of the NCI-funded Cancer Research Network (CRN) and academic partners. Our comprehensive research program in GPM for colorectal cancer will have two main components: 1) secondary data collection through evidence synthesis and cost-effectiveness analysis, and 2) primary data collection through a proof-of-principle study to examine questions about personalized medicine for colorectal cancer. In the proof-of-principle study, we will evaluate the utilization of KRAS and Lynch Syndrome genetic tests within our health systems, and measure the effectiveness of KRAS testing compared with a patient population that does not receive testing. We will also conduct patient and physician interviews to measure psychosocial issues related to KRAS testing, and to help us understand how the genetic test results are used to inform decisions. Our research program in colorectal cancer will build the experience, data systems, and methods that can apply to other cancer-related genetic or molecular tests in the future, such as UGT1A1 testing, or Oncotype DX and CYP2D6 testing for breast cancer. The interwoven research program that we propose will provide opportunities for synergy between teams of researchers conducting primary and secondary data collection. PUBLIC HEALTH RELEVANCE: We will study several genetic tests related to colon cancer that may help doctors understand who will get colon cancer and what therapies some patients should receive. We will study who gets tested, how the genetic test result helps people decide what to do, and whether patients have different health outcomes when they get tested. We will also summarize research that has already been published and analyze cost information about the use of these tests.


The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations.
Authors: Panattoni L. , Lieu T.A. , Jayasekera J. , O'Neill S. , Mandelblatt J.S. , Etzioni R. , Phelps C.E. , Ramsey S.D. .
Source: Breast cancer research and treatment, 2019 Jan; 173(2), p. 417-427.
EPub date: 2018-10-10.
PMID: 30306429
Related Citations

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.
Authors: Chandler Y. , Schechter C.B. , Jayasekera J. , Near A. , O'Neill S.C. , Isaacs C. , Phelps C.E. , Ray G.T. , Lieu T.A. , Ramsey S. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-20; 36(6), p. 554-562.
EPub date: 2018-01-08.
PMID: 29309250
Related Citations

Oncologist and organizational factors associated with variation in breast cancer multigene testing.
Authors: Lieu T.A. , Ray G.T. , Prausnitz S.R. , Habel L.A. , Alexeeff S. , Li Y. , Ramsey S.D. , Phelps C.E. , Chawla N. , C O'Neill S. , et al. .
Source: Breast cancer research and treatment, 2017 May; 163(1), p. 167-176.
EPub date: 2017-02-21.
PMID: 28224383
Related Citations

Breast cancer multigene testing trends and impact on chemotherapy use.
Authors: Ray G.T. , Mandelblatt J. , Habel L.A. , Ramsey S. , Kushi L.H. , Li Y. , Lieu T.A. .
Source: The American journal of managed care, 2016-05-01; 22(5), p. e153-60.
EPub date: 2016-05-01.
PMID: 27266581
Related Citations

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.
Authors: Feigelson H.S. , Zeng C. , Pawloski P.A. , Onitilo A.A. , Richards C.S. , Johnson M.A. , Kauffman T.L. , Webster J. , Nyirenda C. , Alexander G.L. , et al. .
Source: PloS one, 2014; 9(5), p. e94977.
EPub date: 2014-05-01.
PMID: 24788807
Related Citations

Oncologists' attitudes toward KRAS testing: a multisite study.
Authors: Harris J.N. , Liljestrand P. , Alexander G.L. , Goddard K.A. , Kauffman T. , Kolevska T. , McCarty C. , O'Neill S. , Pawloski P. , Rahm A. , et al. .
Source: Cancer medicine, 2013 Dec; 2(6), p. 881-8.
EPub date: 2013-10-02.
PMID: 24403261
Related Citations

Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer.
Authors: Cross D.S. , Rahm A.K. , Kauffman T.L. , Webster J. , Le A.Q. , Spencer Feigelson H. , Alexander G. , Meier P. , Onitilo A.A. , Pawloski P.A. , et al. .
Source: Genetics in medicine : official journal of the American College of Medical Genetics, 2013 Dec; 15(12), p. 933-40.
EPub date: 2013-05-02.
PMID: 23639899
Related Citations

A standardized relative resource cost model for medical care: application to cancer control programs.
Authors: O'Keeffe-Rosetti M.C. , Hornbrook M.C. , Fishman P.A. , Ritzwoller D.P. , Keast E.M. , Staab J. , Lafata J.E. , Salloum R. .
Source: Journal of the National Cancer Institute. Monographs, 2013; 2013(46), p. 106-16.
PMID: 23962514
Related Citations

The challenge of conducting comparative effectiveness research in cancer: the impact of a fragmented U.S. health-care system.
Authors: Fishman P.A. , Hornbrook M.C. , Ritzwoller D.P. , O'Keeffe-Rosetti M.C. , Lafata J.E. , Salloum R.G. .
Source: Journal of the National Cancer Institute. Monographs, 2013; 2013(46), p. 99-105.
PMID: 23962513
Related Citations

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.
Authors: Webster J. , Kauffman T.L. , Feigelson H.S. , Pawloski P.A. , Onitilo A.A. , Potosky A.L. , Cross D. , Meier P.R. , Mirabedi A.S. , Delate T. , et al. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2013 Jan; 22(1), p. 91-101.
EPub date: 2012-11-15.
PMID: 23155138
Related Citations

Evaluating genomic tests from bench to bedside: a practical framework.
Authors: Lin J.S. , Thompson M. , Goddard K.A. , Piper M.A. , Heneghan C. , Whitlock E.P. .
Source: BMC medical informatics and decision making, 2012-10-19; 12, p. 117.
EPub date: 2012-10-19.
PMID: 23078403
Related Citations

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.
Authors: Goddard K.A. , Knaus W.A. , Whitlock E. , Lyman G.H. , Feigelson H.S. , Schully S.D. , Ramsey S. , Tunis S. , Freedman A.N. , Khoury M.J. , et al. .
Source: Genetics in medicine : official journal of the American College of Medical Genetics, 2012 Jul; 14(7), p. 633-42.
PMID: 22516979
Related Citations

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
Authors: Feigelson H.S. , Goddard K.A. , Johnson M.A. , Funk K.C. , Rahm A.K. , Kauffman T.L. , Chitale D.A. , Le Marchand L. , Richards C.S. .
Source: BMC research notes, 2012-04-25; 5, p. 196.
EPub date: 2012-04-25.
PMID: 22534075
Related Citations

Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
Authors: Lin J.S. , Webber E.M. , Senger C.A. , Holmes R.S. , Whitlock E.P. .
Source: American journal of cancer research, 2011-05-15; 1(5), p. 650-62.
PMID: 21779535
Related Citations

Back to Top